AI Clinical Trial Companies Raise Combined $129.5M in Funding Rounds

Iterative Health has closed a $77 million Series C financing round, while Biorce has secured $52.5 million in a Series A round, as AI-driven clinical research companies attract significant investment to address systemic challenges in trial execution and design.

Clinical trials face systematic challenges that delay the delivery of new therapies. More than half of research sites enroll one or fewer patients per study, and nearly 90% of US-based trials fail to meet enrollment targets on time.

Iterative Health's $77 million Series C was led by Intrepid Growth Partners and GV (Google Ventures), with new investment from EDBI and participation from existing investors Insight Partners and Obvious Ventures. The company is building a multispecialty clinical research network that embeds research directly into clinical care. Its global network includes more than 100 research sites across North America, Europe, India, and Australia, and partnerships with over 40 pharmaceutical, biotech, medical device, and contract research organizations. Compared to industry benchmarks for IBD trials, the network delivers 2x faster site activation, reducing startup timelines by up to 3 months, and 3x higher patient enrollment rates.

The new funding will support expansion into additional therapeutic areas beyond gastroenterology and hepatology, including cardiology and obesity, as well as continued geographic growth. As part of the financing, Ajay Agrawal, Co-Founder and Partner at Intrepid Growth Partners, will join Iterative Health's Board of Directors, and Anthony Philippakis, General Partner at GV, will join as a board observer.

Biorce closed a USD $52.5 million Series A round, described as the largest Series A to date in the Iberian healthtech and AI space. The round was led by DST Global Partners, with existing investors Norrsken VC and YZR Capital participating, alongside new investors Mustard Seed Maze and Endeavor Catalyst. The company is building an AI-native infrastructure for clinical trials with its core product, Aika, which helps pharmaceutical companies and contract research organizations design better trial protocols, anticipate regulatory risks, and reduce costly amendments.

Clinical trial management represents an estimated $120 billion in annual global spend. Biorce claims its platform can reduce development timelines by up to 50% by leveraging a data foundation of around one million historical clinical trials. The funding caps a rapid 12-month trajectory in which Biorce raised three rounds, bringing total capital to more than $60 million.

The new investment will support international expansion, particularly in the United States, with a planned presence in Austin, Texas, and the scaling of its engineering and commercial teams. In Barcelona, the company is preparing to move into the former AstraZeneca offices and aims to grow to 250 employees by the end of 2026.